| 0.5681 0.018 (3.27%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.69 | 1-year : | 0.8 |
| Resists | First : | 0.59 | Second : | 0.69 |
| Pivot price | 0.54 |
|||
| Supports | First : | 0.51 | Second : | 0.46 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.54 |
| MA(100) : | 0.68  |
MA(250) : | 0.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 64.4 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 1.75 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FEMY ] has closed below upper band by 17.0%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.6 |
| Low: | 0.55 - 0.55 | 0.55 - 0.55 |
| Close: | 0.56 - 0.57 | 0.57 - 0.57 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Tue, 10 Mar 2026
Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan
Tue, 10 Mar 2026
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment - Sahm
Thu, 26 Feb 2026
New non-surgical permanent birth control clears key global quality hurdle - Stock Titan
Thu, 26 Feb 2026
Femasys Announces FemBloc® Permanent Birth Control Has - GlobeNewswire
Mon, 23 Feb 2026
AMA procedure code supports new infertility option for over 10M US women - Stock Titan
Fri, 20 Feb 2026
Femasys (NASDAQ: FEMY) CFO receives 342,000 restricted stock units - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 60 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 2,070 (K) |
| Shares Short P.Month | 1,920 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -501 % |
| Return on Assets (ttm) | -69.4 % |
| Return on Equity (ttm) | -376.3 % |
| Qtrly Rev. Growth | 31.3 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 5.68 |
| Price to Sales | 16.4 |
| Price to Cash Flow | -1.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|